L-Thyroxine Supplementation for Preterm Newborns Less Than 32 Weeks of Gestation With Hypothyroxinemia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01306227|
Recruitment Status : Completed
First Posted : March 1, 2011
Last Update Posted : August 10, 2018
Transient hypothyroxinemia of prematurity (THOP) is associated with neurodevelopmental impairment in preterm newborns < 32 weeks of gestation (WG). It is not known whether L-Thyroxine supplementation for preterm newborns <32 WG with THOP is beneficial.
The purpose of this study is to compare L-thyroxine treatment vs. placebo in newborn less than 32 WG with THOP.
The primary endpoint is the neurodevelopmental outcome at two years of life, assessed by the Brunet-Lézine score. The secondary endpoints are: death, bronchopulmonary dysplasia (oxygen therapy at 28 days of life and at 36 weeks of postnatal age), patent ductus arteriosus, shock requiring fluid loading or vasoactive treatments, enterocolitis, intraventricular hemorrhage, retinopathy of prematurity, deafness.
|Condition or disease||Intervention/treatment||Phase|
|Hypothyroxinemia||Drug: L-Thyroxine Drug: water||Phase 3|
Preterm newborns <32 weeks of gestation (WG) are screened for THOP between day 5 and day 7 of life. THOP is defined by thyroid-stimulating hormone (TSH) < 20 mIU/L and FT4 < 0.80 ng/dL. After obtaining written consent from the parents, preterm newborns <32 WG with THOP will be included. Randomization is stratified by center and 2 age-groups (24-28 WG and 29-32 WG). One arm will receive L-thyroxine treatment and the other arm will receive placebo. Treatment will be started within one week after diagnosis and will last 6 weeks. TSH and FT4 will be assayed 2 weeks after stopping treatment.
The primary endpoint is the neurodevelopmental outcome at two years of life, assessed by the Brunet-Lézine score.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||50 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||L-Thyroxine Supplementation for Preterm Newborns Less Than 32 Weeks of Gestation With Transient Hypothyroxinemia of Prematurity: a Prospective Randomized Double-blind Trial|
|Actual Study Start Date :||September 1, 2006|
|Actual Primary Completion Date :||December 31, 2014|
|Actual Study Completion Date :||December 31, 2017|
Placebo Comparator: water
Oral treatment with water for 6 weeks
Oral treatment with water. Equal number of drop of water as compared with the treatment arm (according to the body weight of the newborn) in the morning, once a day.
Oral treatment with L-Thyroxine for 6 weeks
Treatment with L-Thyroxine:7,5 µg/kg/day. Oral treatment (one drop =5µg) in the morning, once a day.
- Neurodevelopmental outcome [ Time Frame: 2 years old ]Brunet-Lézine score
- Morbidity associated with management of newborns < 32 WG with hypothyroxinemia [ Time Frame: discharge, 1 year, 2 years ]
- Bronchopulmonary dysplasia (oxygen therapy at 28 days of life and at 36 weeks of postnatal age)
- Patent ductus arteriosus,
- Shock requiring fluid loading or vasoactive treatments
- Intraventricular hemorrhage
- Retinopathy of prematurity
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01306227
|Caen University Hospital|
|Caen, Basse Normandie, France, 14033|
|Lens, Nord- Pas De Calais, France, 62307|
|Amiens University Hospital|
|Amiens, Picardie, France, 80054|
|Principal Investigator:||Pierre Tourneux, MD||Amiens University Hospital|